Neos Therapeutics Inc (NEOS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Vipin K. Garg
Employees:
215
2940 N. HIGHWAY 360, SUITE 400, GRAND PRAIRIE, TX 75050
972.408.1360

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Neos Therapeutics, Inc. operates as a pharmaceutical company, which engages in developing, manufacturing, and commercializing products using proprietary, extended-release drug delivery technology platform. It uses this technology to develop products for the treatment of attention deficit hyperactivity disorder (ADHD), including an extended-release orally disintegrating tablet. The company was founded on June 15, 2009 and is headquartered in Grand Prairie, TX.

Data derived from most recent annual or quarterly report
Market Cap 57.22 Million Shares Outstanding49.757 Million Avg 30-day Volume 10.319 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.37
Price to Revenue0.463 Debt to Equity-1.9712 EBITDA-5.642 Million
Price to Book Value0.0 Operating Margin-23.5011 Enterprise Value54.154 Million
Current Ratio0.655 EPS Growth-0.048 Quick Ratio0.493
1 Yr BETA 1.1743 52-week High/Low 0.0 / Profit Margin-41.4121
Operating Cash Flow Growth62.9124 Free Cash Flow to Firm (FCFF) TTM 200 Free Cash Flow to Equity (FCFE) TTM205.15 Million
Altman Z-Score-7.6072
View SEC Filings from NEOS instead.

View recent insider trading info

Neos Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding NEOS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NEOS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2021-03-19 by LIMONGELLI JOHN M
  • 4: filed on 2021-03-19 by ROBINSON JAMES A. JR.
  • 4: filed on 2021-03-19 by MCLAUGHLIN GERALD W.
  • 4: filed on 2021-03-19 by HECHT BETH
  • 4: filed on 2021-03-19 by SCHMID JOHN P.
  • 4: filed on 2021-03-19 by FONG BRYANT
  • 4: filed on 2021-03-19 by SZYPER LINDA M
  • 4: filed on 2021-03-19 by ROBITAILLE GREGORY J
  • 4: filed on 2021-03-19 by HELLER ALAN L
  • 4: filed on 2021-03-19 by EISENSTADT RICHARD I

    • Events (8k)

  • 8-K: filed on 2021-03-22:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
  • 8-K: filed on 2021-02-08:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-01-11:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-12-30:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-12-11:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-12-10:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2020-06-19:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2020-06-11:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    HELLER ALAN L

    • Director
    		 No longer subject to file 2021-03-19 0

    ROBITAILLE GREGORY J

    • Director
    		 No longer subject to file 2021-03-19 0

    LIMONGELLI JOHN M SVP & GENERAL COUNSEL

    • Officer
    		 No longer subject to file 2021-03-19 0

    SCHMID JOHN P.

    • Director
    		 No longer subject to file 2021-03-19 0

    MCLAUGHLIN GERALD W. CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 No longer subject to file 2021-03-19 0

    EISENSTADT RICHARD I CHIEF FINANCIAL OFFICER

    • Officer
    		 No longer subject to file 2021-03-19 0

    FONG BRYANT

    • Director
    		 No longer subject to file 2021-03-19 0

    HECHT BETH

    • Director
    		 No longer subject to file 2021-03-19 0

    ROBINSON JAMES A. JR.

    • Director
    		 No longer subject to file 2021-03-19 0

    SZYPER LINDA M

    • Director
    		 No longer subject to file 2021-03-19 0

    MCDONNELL THOMAS P CHIEF COMMERCIAL OFFICER

    • Officer
    		 35,864 2018-05-01 0

    GARG VIPIN K CHIEF EXECUTIVE OFFICER

    • Officer
    		 160,748 2018-03-01 0

    ENGELKING DOROTHY VP, REGULATORY AFFAIRS

    • Officer
    		 10,416 2018-03-01 0

    EDICK PAUL R

    • Director
    		 0 2017-07-03 0

    MARTENS JUERGEN CHIEF TECH/OPERATIONS OFFICER

    • Officer
    		 25,000 2017-05-01 0

    SCHULER JACK W

    • 10% Owner
    		 2,338,671 2017-02-17 0

    PRESIDIO PARTNERS 2007, L.P.

    PRESIDIO PARTNERS 2007 (PARALLEL), L.P.

    PRESIDIO PARTNERS 2007 GP, L.P.

    COLLIER DAVID J

    WATSON JAMES F

    PRESIDIO PARTNERS 2007 GP, LLC

    SOHAIL FAYSAL A.

    • 10% Owner
    		 1,599,993 2016-04-18 0

    TENGLER MARK CHIEF TECHNOLOGY OFFICER

    • Officer
    		 0 2015-09-01 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MANAGEMENT CO

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD MGMT III, L.P.

    DEERFIELD PRIVATE DESIGN FUND III, L.P.

    • 10% Owner
    • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
    		 No longer subject to file 2015-07-28 0

    BLUHM ANDREW G

    DELAWARE STREET CAPITAL MASTER FUND, L.P.

    DSC ADVISORS, L.L.C.

    DSC ADVISORS, L.P.

    DSC MANAGERS, L.L.C.

    DELAWARE STREET CAPITAL L P

    • 10% Owner
    		 No longer subject to file 2015-07-28 0

    KEARNY VENTURE ASSOICATES II LLC

    BURRILL LIFE SCIENES CAPITAL FUND III L P

    CASTELEIN CALEY

    DALAL ANUPAM

    • 10% Owner
    		 No longer subject to file 2015-07-28 0

    IANNELLI RALPH

    ESSEX CAPITAL CORP

    • 10% Owner
    		 No longer subject to file 2015-07-28 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    NEOS THERAPEUTICS INC NEOS 2021-03-19 22:15:03 UTC -49.5722 49.6422 700000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 21:45:03 UTC -43.4657 43.5357 700000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 21:15:03 UTC -43.4657 43.5357 700000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 20:45:03 UTC -43.124 43.194 700000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 20:15:03 UTC -43.124 43.194 700000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 19:45:03 UTC -43.124 43.194 700000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 19:15:03 UTC -43.124 43.194 700000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 18:45:03 UTC -37.2566 37.3266 700000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 18:15:03 UTC -37.2566 37.3266 700000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 17:45:03 UTC -37.2566 37.3266 700000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 17:15:03 UTC -37.2566 37.3266 750000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 16:45:03 UTC -48.4169 48.4869 750000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 16:15:03 UTC -48.4169 48.4869 800000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 15:45:03 UTC -48.4169 48.4869 600000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 15:15:03 UTC -48.4169 48.4869 600000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 14:45:03 UTC -48.4169 48.4869 700000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 14:15:03 UTC -48.4169 48.4869 700000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 13:45:03 UTC -48.4169 48.4869 700000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 13:15:03 UTC -48.4169 48.4869 700000
    NEOS THERAPEUTICS INC NEOS 2021-03-19 12:45:03 UTC -48.4169 48.4869 450000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments